<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829060</url>
  </required_header>
  <id_info>
    <org_study_id>160158</org_study_id>
    <nct_id>NCT02829060</nct_id>
  </id_info>
  <brief_title>Endourology Disease Group Excellence (EDGE) Consortium: Antibiotics (Abx) for Percutaneous Nephrolithotomy (PCNL) Part 2</brief_title>
  <acronym>PNLABXPART2</acronym>
  <official_title>The Endourology Disease Group for Excellence (EDGE) Consortium: A Randomized Trial of Preoperative Prophylactic Antibiotics Prior to Percutaneous Nephrolithotomy in Patients With Moderate Risk of Postoperative Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be a multi-institutional randomized clinical trial of a short course of&#xD;
      pre-operative antibiotic prophylaxis in addition to perioperative antibiotics prior to&#xD;
      undergoing percutaneous nephrolithotomy. The select patient population will be those patients&#xD;
      deemed to be at a moderately increased risk of postoperative infectious complications. These&#xD;
      higher risk patients are those with indwelling urinary drainage tubes and those with a&#xD;
      positive preoperative urine culture.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be a multi-institutional randomized clinical trial of a short course of&#xD;
      pre-operative antibiotic prophylaxis in addition to perioperative antibiotics. Once patients&#xD;
      have been identified and enrolled into the study, they will be grouped based on the&#xD;
      sensitivity profiles of their positive urine culture or the presence of indwelling kidney&#xD;
      drain tube (nephrostomy tube, nephroureteral stent, ureteral stent). Each of these groups&#xD;
      will be individually randomized as follows:&#xD;
&#xD;
      Group 1) Kidney stone subjects with indwelling drain tube (nephrostomy tube or ureteral&#xD;
      stent) and negative urine culture&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
        -  7 day course of oral Macrobid (Nitrofurantoin) 100 mg twice daily + &lt;24 hours&#xD;
           perioperative intravenous (IV) antibiotics&#xD;
&#xD;
        -  48 hours perioperative oral Macrobid (Nitrofurantoin) 100mg twice daily + &lt;24 hours&#xD;
           perioperative IV antibiotics&#xD;
&#xD;
      Group 2) Kidney stone subjects with positive urine culture sensitive to oral antibiotics&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
        -  7 day course of an oral antibiotic (proven effective on sensitivity profile) + &lt;24 hours&#xD;
           perioperative IV antibiotics&#xD;
&#xD;
        -  48 hours of an oral antibiotic (proven effective on sensitivity profile) + &lt;24 hours&#xD;
           perioperative IV antibiotics&#xD;
&#xD;
      Macrobid is preferred oral agent if shown to be effective per culture sensitivities. If&#xD;
      patient has previous allergies to Macrobid and/or sensitivity profile indicates&#xD;
      ineffectiveness of Macrobid, the one antibiotic will be provided in the order of choice:&#xD;
      nitrofurantoin &gt; sulfamethoxazole-trimethoprim &gt; doxycycline&gt; ciprofloxacin &gt; keflex &gt;&#xD;
      cefpodoxime.&#xD;
&#xD;
      Group 3) Kidney stone subject with positive urine culture sensitive to only&#xD;
      intravenous/intramuscular antibiotics (resistant to oral agents)&#xD;
&#xD;
      Randomization:&#xD;
&#xD;
        -  7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity&#xD;
           profile) + &lt;24 hours perioperative IV antibiotics&#xD;
&#xD;
        -  48 hours of an IV/IM antibiotic (proven effective on sensitivity profile) + &lt;24 hours&#xD;
           perioperative IV antibiotics peripherally inserted central catheter (PICC) line, IV or&#xD;
           intramuscular injection for administration of antibiotics.&#xD;
&#xD;
      The participating institutions are academic medical centers in the United States and Canada&#xD;
      that are part of the EDGE (Endourologic Disease Group of Excellence) research consortium, a&#xD;
      research collaborative that has the goal of producing high quality, multi-institutional&#xD;
      studies of nephrolithiasis. Separate IRB approvals will be obtained from each institution.&#xD;
      University of California San Diego (UCSD) will be the coordinating institution. Member&#xD;
      institution of EDGE maintain frequent email contact with one another and hold a monthly&#xD;
      teleconference to discuss safety updates, interim results, issues with accrual, and&#xD;
      modifications to research protocols and consents (if necessary).&#xD;
&#xD;
      Treatment Assignments:&#xD;
&#xD;
      Patients will be assigned based on a predetermined allocation sequence that will be generated&#xD;
      by a computerized random number generator. Patients will be stratified by institution in&#xD;
      permuted blocks of varying size. Only study staff at the coordinating institution (UCSD) will&#xD;
      have access to the full allocation sequence. i.e. no clinical staff involved in recruiting&#xD;
      and consenting patients for the study at UCSD or other participating institutions will have&#xD;
      knowledge of the allocation sequence at their institution prior to enrollment of each&#xD;
      patient. To further aid allocation concealment, the block size will be varied.&#xD;
&#xD;
      Standard of care procedures:&#xD;
&#xD;
      Patients will be identified based on clinic visits or hospital admission. All patients will&#xD;
      be counseled on standard treatment options-extracorporeal shock wave lithotripsy (ESWL),&#xD;
      percutaneous nephrolithotomy (PCNL) and ureteroscopy (URS). The discussion regarding&#xD;
      treatment options and subsequent care will not deviate from routine care. Patients consenting&#xD;
      for percutaneous nephrolithotomy (PCNL) will be considered for enrollment into the study and&#xD;
      will be enrolled to have data collected prospectively. Patients will be consented prior to&#xD;
      prescription of antibiotics and to the surgery for collection of demographic, disease,&#xD;
      perioperative, and postoperative data. Abdominal pelvic computed tomography (CT), if not&#xD;
      already obtained, will be used to delineate pre-operative stone size and for preoperative&#xD;
      planning. If the patient does not consent to the study, the use of antibiotics will be based&#xD;
      on routine clinical practice of the treating urologist. Both prophylaxis with preoperative&#xD;
      antibiotics and no prophylaxis (i.e. periprocedural only) are considered standard of care.&#xD;
&#xD;
      Investigational portion of treatment:&#xD;
&#xD;
      Group 1 patients will be randomized to nitrofurantoin monohydrate/macrocrystalline 100 mg&#xD;
      twice daily for 7 days prior to PCNL with the final day of prophylactic course being 1 day&#xD;
      prior to surgery or to nitrofurantoin monohydrate/macrocrystalline 100mg twice daily for 48&#xD;
      hours prior to PCNL. Nitrofurantoin monohydrate/macrocrystalline is currently indicated for&#xD;
      the treatment of acute uncomplicated urinary tract infections. Both groups will receive&#xD;
      antibiotics the day of surgery-i.e. a dose of ampicillin intravenous (IV) (2 g) and&#xD;
      gentamicin intravenous (IV) (5 mg/kg) within 120 minutes of surgery start time. Patients with&#xD;
      penicillin allergy will receive vancomycin intravenous (IV) (1 g) instead of ampicillin and&#xD;
      patients with gentamicin/aminoglycoside allergy will receive ceftriaxone intravenous (IV) (2&#xD;
      g) instead of gentamicin. Postoperative antibiotics in the absence of sepsis (see definition&#xD;
      of sepsis below) will be &lt;24 hours of IV antibiotics.&#xD;
&#xD;
      Group 2 patients will be randomized to either 7 days or 48 hours of oral antibiotics prior to&#xD;
      the PCNL with the final day of prophylactic course being 1 day prior to surgery. Antibiotic&#xD;
      choice will be determined by the culture sensitivity profile, with nitrofurantoin&#xD;
      monohydrate/macrocrystalline 100 mg twice daily being the preferred agent if shown to be&#xD;
      effective against the uropathogen(s). If patient has previous allergies to Macrobid and/or&#xD;
      sensitivity profile indicates ineffectiveness of Macrobid, then one antibiotic will be&#xD;
      provided in the following order: nitrofurantoin &gt; sulfamethoxazole-trimethoprim &gt;&#xD;
      doxycycline&gt; ciprofloxacin &gt; keflex &gt; cefpodoxime.&#xD;
&#xD;
      Antibiotics the day of surgery will be a dose of ampicillin IV (2g) and gentamicin IV&#xD;
      (5mg/kg) within 120 minutes of surgery start time. Patients with penicillin allergy will&#xD;
      receive vancomycin IV (1g) instead of ampicillin and patients with gentamicin/aminoglycoside&#xD;
      allergy will receive ceftriaxone IV (2g) instead of gentamicin. Postoperative antibiotics in&#xD;
      the absence of sepsis (see definition of sepsis below) will be &lt;24 hours of IV antibiotics.&#xD;
&#xD;
      Group 3 patients will be randomized to either 7 days or 48 hours of an injectable (IV/IM)&#xD;
      antibiotic prior to the PCNL with the final day of prophylaxis being 1 day before surgery.&#xD;
      Antibiotic choice will be determined by the culture sensitivity profile.&#xD;
&#xD;
      Antibiotics the day of surgery will be a dose of same IV/IM antibiotic within 120 minutes of&#xD;
      surgery start time. Postoperative antibiotics in the absence of sepsis (see definition of&#xD;
      sepsis below) will be &lt;24 hours of IV antibiotics.&#xD;
&#xD;
      Central randomization will take place with UCSD as the lead site. Randomization will occur in&#xD;
      block randomization in block sizes of 10.&#xD;
&#xD;
      Standard of care procedures:&#xD;
&#xD;
      Patients will have PCNL performed in typical fashion, without deviation from standard of&#xD;
      care. Per the usual practice of the treating surgeon, percutaneous access to the kidney will&#xD;
      be obtained either by Interventional Radiology or by the operating surgeon. At the time of&#xD;
      surgery, urine from the renal pelvis, urine from the bladder, and the stone itself will be&#xD;
      sent for culture. Placement of renal drainage devices (ureteral stents, nephrostomy tubes,&#xD;
      nephroureteral stents) will be left up to the discretion of the surgeon. Post-operatively,&#xD;
      the patients will be admitted to the hospital and monitored per usual clinical procedure.&#xD;
      Unless clinically indicated as described above, &lt;24 hours of post-operative antibiotics will&#xD;
      be prescribed. Labs will be obtained pre-operatively and on post-operative day 1 if the&#xD;
      patient is admitted, and will include: complete blood count (CBC), basic metabolic panel&#xD;
      (chem 7). Further laboratory tests will be dictated by the patients' clinical status as per&#xD;
      the standard of care-i.e. for patients that exhibit signs of sepsis such as tachycardia&#xD;
      (&gt;90/min), low systolic blood pressure (&lt;90 mmHg), fever &gt; 38.3 Celsius, hypothermia &lt;36&#xD;
      Celsius, altered mental status, respiratory rate &gt;20 min or leukocytosis &gt;12000 or leukopenia&#xD;
      &lt;4000, further urine culture, blood culture and serum lactate will be obtained.&#xD;
&#xD;
      The patient will be discharged from the hospital per the usual clinical protocols.&#xD;
      Post-discharge the patient will be seen in clinic 1-12 weeks after surgery. Patients will&#xD;
      undergo a non-contrast CT abdomen/pelvis, an abdominal plain radiograph, and/or a renal&#xD;
      ultrasound during this postoperative period.&#xD;
&#xD;
      Demographic fields will be obtained preoperatively and include age, race, gender, American&#xD;
      Society of Anesthesiologists (ASA) score (for comorbidity assessment), body mass index (BMI),&#xD;
      and prior stone disease. Disease fields that will be obtained include stone size (maximal&#xD;
      axial and coronal dimensions), degree of hydronephrosis (mild/moderate/severe), history of&#xD;
      diabetes mellitus, history of cardiac disease, hypertension, prior urinary tract infection,&#xD;
      history of bowel diversion, or neurogenic bladder.&#xD;
&#xD;
      Perioperative fields include OR (surgical) time, type of anesthesia, number of access tracts,&#xD;
      use of internalized ureteral stent, nephrostomy tube, or nephroureteral stent, estimated&#xD;
      blood loss, and intraoperative complications. Postoperative fields will include postoperative&#xD;
      maximum body temperature, heart rate, respiratory rate, urine culture results, stone culture&#xD;
      results, stone composition, white blood cell count, serum lactate, postoperative serum&#xD;
      creatinine, need for admission to intensive care unit, hospital length of stay (LOS), and&#xD;
      stone-free status at 1-12 week postoperative imaging. Patients will be followed during&#xD;
      routine clinical visits as part of their continuing care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Anticipated">January 2025</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postoperative sepsis</measure>
    <time_frame>30 days</time_frame>
    <description>Sepsis will be defined by the 2012 International Guidelines for the Management of Severe Sepsis and Septic Shock where 2 or more of the following variables are present and temporally associated&#xD;
Temp &gt; 38.3C or &lt;36C&#xD;
Heart Rate &gt; 90/min (at least 12 hrs after surgery)&#xD;
Respiratory Rate &gt;20/min (at least 12 hrs after surgery)&#xD;
Altered mental status: defined as lack of orientation to either name, place or time/date&#xD;
Systolic Blood Pressure (SBP) &lt;90 mmHg, Mean Arterial Pressure &lt;70 mmHg, or SBP decrease &gt;40 mmHg in adults&#xD;
White blood cell (WBC) &gt; 12000 or &lt;4000</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>rate of nonseptic bacteruria</measure>
    <time_frame>30 days</time_frame>
    <description>-non septic bacteria is the presence of any colony forming units on urine culture where sepsis is not present</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stone-free rate</measure>
    <time_frame>30 days</time_frame>
    <description>stone free defined as absence of kidney stone on all post-operative imaging (plain kidney-ureter-bladder X-ray or renal ultrasound or computed tomography)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>30 days</time_frame>
    <description>hospital day defined as any inpatient stay &lt; or = 24 hours</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Nephrolithiasis</condition>
  <condition>Urinary Tract Infection (UTI)</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>1a: Indwelling drains (48 hr)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has indwelling urinary tubes/drains and a negative urine culture&#xD;
Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b: Indwelling drains (7d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has indwelling urinary tubes/drains and a negative urine culture&#xD;
Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2a: +UCx with Oral Options (48hr)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has a positive pre-operative urine culture with oral antibiotic options&#xD;
Nitrofurantoin (Macrobid) 100 mg oral bid for 48 hours prior to surgery&#xD;
If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin &gt; sulfamethoxazole-trimethoprim &gt; doxycycline&gt; ciprofloxacin &gt; cephalexin &gt; cefpodoxime.&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2b: +UCx with Oral Options (7d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has a positive pre-operative urine culture with oral antibiotic options&#xD;
Nitrofurantoin (Macrobid) 100 mg oral bid for 7 days prior to surgery&#xD;
If patient has previous allergies to Macrobid and/or sensitivity profile indicates Macrobid resistance, then one antibiotic will be provided in the following order: nitrofurantoin &gt; sulfamethoxazole-trimethoprim &gt; doxycycline&gt; ciprofloxacin &gt; cephalexin &gt; cefpodoxime.&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3a: +UCx No Oral options (48hr)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities&#xD;
48 hour course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)&#xD;
Gentamicin (80 mg) preferred if sensitive&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3b: +UCx No Oral options (7d)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group has a positive pre-operative urine culture with no oral antibiotic options based on culture sensitivities&#xD;
7 day course of an IV/Intramuscular (IM) antibiotic (proven effective on sensitivity profile)&#xD;
Gentamicin (80 mg) preferred if sensitive&#xD;
All patient receive ampicillin IV (2 g) and gentamicin IV (5 mg/kg) within 120 minutes of surgery start time.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin 100 MG, 7d</intervention_name>
    <description>7 day course, 100 mg twice daily, PO</description>
    <arm_group_label>1b: Indwelling drains (7d)</arm_group_label>
    <arm_group_label>2b: +UCx with Oral Options (7d)</arm_group_label>
    <other_name>Macrobid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin, 5mg/kg</intervention_name>
    <description>Peri-operative dose: 5 mg/kg of ideal body weight, IV</description>
    <arm_group_label>1a: Indwelling drains (48 hr)</arm_group_label>
    <arm_group_label>1b: Indwelling drains (7d)</arm_group_label>
    <arm_group_label>2a: +UCx with Oral Options (48hr)</arm_group_label>
    <arm_group_label>2b: +UCx with Oral Options (7d)</arm_group_label>
    <arm_group_label>3a: +UCx No Oral options (48hr)</arm_group_label>
    <arm_group_label>3b: +UCx No Oral options (7d)</arm_group_label>
    <other_name>Gentamicin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ampicillin 2g</intervention_name>
    <description>Peri-operative dose: 2 grams, IV</description>
    <arm_group_label>1a: Indwelling drains (48 hr)</arm_group_label>
    <arm_group_label>1b: Indwelling drains (7d)</arm_group_label>
    <arm_group_label>2a: +UCx with Oral Options (48hr)</arm_group_label>
    <arm_group_label>2b: +UCx with Oral Options (7d)</arm_group_label>
    <arm_group_label>3a: +UCx No Oral options (48hr)</arm_group_label>
    <arm_group_label>3b: +UCx No Oral options (7d)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrofurantoin 100 mg, 48 hrs</intervention_name>
    <description>48 hour course, 100 mg twice daily, PO</description>
    <arm_group_label>1a: Indwelling drains (48 hr)</arm_group_label>
    <arm_group_label>2a: +UCx with Oral Options (48hr)</arm_group_label>
    <other_name>Macrobid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin, 80 mg, 7d</intervention_name>
    <description>7 day course, 80 mg daily, IM or IV</description>
    <arm_group_label>3b: +UCx No Oral options (7d)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gentamicin, 80 mg, 48hr</intervention_name>
    <description>48 hour course, 80 mg daily, IM or IV</description>
    <arm_group_label>3a: +UCx No Oral options (48hr)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Age: &gt;17 years of age&#xD;
&#xD;
        Gender: both men and women included. We anticipated enrolling a study population of&#xD;
        approximately 60% men and 40% women based on a higher incidence of kidney stones among men&#xD;
        in NHANES data.&#xD;
&#xD;
        Ethnic background: all ethnicities will be included in the study population and the&#xD;
        specific ethnic diversity present in the study population will reflect the geographic&#xD;
        distributions of the participating institutions.&#xD;
&#xD;
        Health status: see below for specific inclusion/exclusion criteria.&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Renal stone of any size for which PCNL is recommended&#xD;
&#xD;
          -  Positive preoperative urine culture within 3 months&#xD;
&#xD;
          -  Current internalized ureteral stent, nephrostomy tube, nephroureteral stent&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patients age &lt;18&#xD;
&#xD;
          -  Active pregnancy&#xD;
&#xD;
          -  Patients receiving antibiotic doses (other than prescribed for the study) within the&#xD;
             seven days preceding surgery&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Roger L Sur, MD</last_name>
    <phone>619-543-2628</phone>
    <email>rlsur@ucsd.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joel E Abbott, DO</last_name>
    <phone>619-543-2628</phone>
    <email>jabbott@westernu.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roger L Sur, MD</last_name>
      <phone>619-543-2628</phone>
      <email>rlsur@ucsd.edu</email>
    </contact>
    <contact_backup>
      <last_name>Joel E Abbott, DO</last_name>
      <phone>619-543-2628</phone>
      <email>jabbott@westernu.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Seth K Bechis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>de la Rosette J, Assimos D, Desai M, Gutierrez J, Lingeman J, Scarpa R, Tefekli A; CROES PCNL Study Group. The Clinical Research Office of the Endourological Society Percutaneous Nephrolithotomy Global Study: indications, complications, and outcomes in 5803 patients. J Endourol. 2011 Jan;25(1):11-7. doi: 10.1089/end.2010.0424.</citation>
    <PMID>21247286</PMID>
  </results_reference>
  <results_reference>
    <citation>Korets R, Graversen JA, Kates M, Mues AC, Gupta M. Post-percutaneous nephrolithotomy systemic inflammatory response: a prospective analysis of preoperative urine, renal pelvic urine and stone cultures. J Urol. 2011 Nov;186(5):1899-903. doi: 10.1016/j.juro.2011.06.064. Epub 2011 Sep 23.</citation>
    <PMID>21944106</PMID>
  </results_reference>
  <results_reference>
    <citation>Kumar S, Bag S, Ganesamoni R, Mandal AK, Taneja N, Singh SK. Risk factors for urosepsis following percutaneous nephrolithotomy: role of 1 week of nitrofurantoin in reducing the risk of urosepsis. Urol Res. 2012 Feb;40(1):79-86. doi: 10.1007/s00240-011-0386-6. Epub 2011 May 13.</citation>
    <PMID>21567157</PMID>
  </results_reference>
  <results_reference>
    <citation>Bag S, Kumar S, Taneja N, Sharma V, Mandal AK, Singh SK. One week of nitrofurantoin before percutaneous nephrolithotomy significantly reduces upper tract infection and urosepsis: a prospective controlled study. Urology. 2011 Jan;77(1):45-9. doi: 10.1016/j.urology.2010.03.025. Epub 2010 Jun 8.</citation>
    <PMID>20570319</PMID>
  </results_reference>
  <results_reference>
    <citation>Wolf JS Jr, Bennett CJ, Dmochowski RR, Hollenbeck BK, Pearle MS, Schaeffer AJ; Urologic Surgery Antimicrobial Prophylaxis Best Practice Policy Panel. Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008 Apr;179(4):1379-90. doi: 10.1016/j.juro.2008.01.068. Epub 2008 Feb 20. Erratum in: J Urol. 2008 Nov;180(5):2262-3.</citation>
    <PMID>18280509</PMID>
  </results_reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>May 31, 2016</study_first_submitted>
  <study_first_submitted_qc>July 7, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>March 23, 2020</last_update_submitted>
  <last_update_submitted_qc>March 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Roger L Sur, M.D.</investigator_full_name>
    <investigator_title>Professor of Surgery</investigator_title>
  </responsible_party>
  <keyword>nephrolithiasis</keyword>
  <keyword>percutaneous nephrolithiasis</keyword>
  <keyword>urinary tract infection (UTI)</keyword>
  <keyword>Sepsis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
    <mesh_term>Kidney Calculi</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gentamicins</mesh_term>
    <mesh_term>Ampicillin</mesh_term>
    <mesh_term>Nitrofurantoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>RedCap Password Protected Data Share System</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

